Kornimate/medical-research-clean huggingface dataset:
vest iii pms clinical protocol

Conditions: Coronary Artery Disease

Summary: post marketing surveillance (pms) study. 200 patients will be enrolled in a prospective, multi center, randomized, two-arm, open label, and controlled, enrolling patients with multi vessel atherosclerotic coronary artery disease, scheduled to undergo coronary artery bypass grafting (cabg) with arterial grafting of ima to lad, one saphenous vein graft (svg) to the right territory and one or more svgs to the left territory. of all vein grafts, one will be selected randomly to receive treatment with vest and another designated control.


Eligibility criteria:
inclusion criteria: 1. patient scheduled for on-pump cabg on clinical grounds 2. two or more bypass vein grafts bypasses indicated as follows: one (1) for right coronary artery, 1 or more for left coronary arteries and ima indicated for the lad on clinical grounds 3. appropriately sized and accessible target coronary arteries, with a minimum diameter of 1.5 mm and adequate vascular bed 4. ability to give their informed written consent 5. ability and willingness to comply with study follow up requirements 6. patient is ≥ 18 and ≤ 80 years of age, and has life expectancy ≥5 years exclusion criteria: 1. concomitant non-cabg cardiac procedure 2. prior cardiac surgery 3. emergency cabg surgery (cardiogenic shock, inotropic pressure support, iabp) 4. contraindication for on-pump cabg with cardioplegic arrest (e.g. severely calcified aorta) 5. calcification at the intended anastomotic sites, as assessed upon opening of the chest, before randomization 6. severe vein varicosity 7. prior debilitating stroke less than 1 year before surgery 8. severe renal dysfunction (cr\>2.0 mg/dl or \>177 μmol/l) 9. women of child bearing age 10. concomitant life-threatening disease likely to limit life expectancy to less than 5 years 11. indication for warfarin up to time of surgery 12. inability to tolerate or comply with required normal post-operative drug regimen (antiplatelet, statin and beta-blockers) that cannot adequately be controlled. 13. inability to take aspirin 14. contraindication to intravascular contrast material that cannot be adequately controlled with pre-medication 15. inability to comply with required follow-ups including angiographic and/or ct imaging methods. 16. participating in any other investigational study for either drug or device which can influence collection of valid data under this study
safety margin assessment after rfa using the registration of pre-ablation mri and post-ablation ct

Conditions: HCC; Liver Tumor

Summary: magnetic resonance imaging (mri) has been widely used for small liver lesion detection and characterization. in patients who undergo rfa, mri is often performed before rfa, whereas immediate technical success is usually assessed by ct. conventional visual assessment of two modalities may be more challenging than being anticipated, because acquisition position, respiration, and spatial resolution differ between the two. therefore, the study purpose is to evaluate the results of software-assisted ablative margin assessment using registration of different pre-and post-rfa modalities compared with the conventional method of side-by-side mri-ct comparison in patients with hccs.


Eligibility criteria:
inclusion criteria: * patients (≥ 18 years) who were referred to our radiology department for liver tumor rfa * patients who had liver mr images of sufficient quality for pre-rfa evaluation within 30 days before rfa * patients with 1-3 tumors (\<5 cm) exclusion criteria: * child-pugh class c * any uncorrected coagulopathy * hypersensitivity to iodine or other reasons that prevented the performance of post-rfa contrast-enhanced ct

Keywords: hcc rfa liver tumor
weight variation on cop

Conditions: Adolescent Overweight

Summary: this study will be conducted to investigate the impact of variant weights in adolescents during unperturbed standing conditions.

200 adolescents from both sexes will be assigned to this study. they will be selected randomly from a secondary school student and first level university students. they will be assigned into four group of equal numbers according to (bmi) body mass index for age percentile obese group (n=50), overweight group (n=50), underweight group (n=50) and normal group weight (n=50).the freemed platform and freestep software were used to assess the following parameters for each subject: 1. sway length (mm). 2. the maximum (peak) oscillation of cop. 3. the minimum oscillation of cop.

Eligibility criteria:
inclusion criteria: * their age will be ranging from 16 to 18 years. * the sample will be selected according to (bmi-for age percentile) growth charts according to cdc (centers for disease control and prevention) (appendix-1) (nchs, 2014) * all participant will be free from any musculoskeletal deformities. * all participant are free of peripheral neuropathic diseases. * they have no visual or auditory or vestibular disorders. * they will able to understand, follow and execute instructions included in the testing analysis procedures. exclusion criteria: * all adolescent associated with any musculoskeletal deformities. * all adolescent associated with any foot deformity. * all adolescent had a previous foot orthopedic procedure. * all adolescent has visual or auditory or vestibular disorder. * all adolescent has peripheral neuropathy. * adolescent with morbid obesity bmi \>99th for age percentile (barlow, 2007).
functional outcome in midshaft clavicle fracture, treated with superior versus anteroinferior reconstruction plate

Conditions: Closed Fracture of Shaft of Clavicle

Summary: the purpose of this study was to evaluate the functional outcome in patients with a midshaft clavicle fracture treated with to different techniques. the first one was placing a 3.5mm reconstruction plate in the superior side of the clavicle and the second one placing the same 3.5mm reconstruction plate in the anteroinferior side of the clavicle. the patients had the same rehabilitation program and evaluated with functional scores at 30, 60, 90 and 365 days after surgery. biomechanical studies have demonstrated more stable construct using an anteroinferior plate in clavicle fractures and we were trying to find out if it has a clinical relevance in patients with midshaft clavicle fractures.

the purpose of this study was to evaluate the functional outcome in patients with a midshaft clavicle fracture treated with to different techniques. the first technique was placing a 3.5mm reconstruction plate in the superior side of the clavicle and the second one placing the same 3.5mm reconstruction plate in the anteroinferior side of the clavicle. the patients had the same rehabilitation program and evaluated with disabilities arm shoulder and hand functional outcome score and visual analogue score for pain at 30, 60, 90 and 365 days after surgery. biomechanical studies have demonstrated more stable construct using an anteroinferior plate in clavicle fractures and we were trying to find out if it has a clinical relevance in patients with midshaft clavicle fractures.

Eligibility criteria:
inclusion criteria: * traumatic fracture * ao 15 b1 and 15 b2 * no previous shoulder lesions * no further 7 days fractures * closed fracture exclusion criteria: * calcium diseases * previous shoulder pain * other fractures associated

Keywords: midshaft clavicle fracture functional outcome anteroinferior plate superior plate reconstruction plate
efficacy study of amantadine to treat gait dysfunction and freezing in parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to explore the efficacy of the drug amantadine for the treatment of freezing of gait in patients with parkinson's disease. the investigators hypothesize that amantadine is useful for management of freezing of gait in subjects with parkinson's disease.

subjects who meet the eligibility requirements for the study will be randomized to amantadine versus a matching placebo.

Eligibility criteria:
inclusion criteria: 1. subjects with idiopathic pd as determined by uk brain bank diagnostic criteria 2. h\&y stage 2.5-3 3. presence of freezing of gait (fog) as determined by updrs part i score \> 2 4. ability to walk for 2 minutes in the on and off state 5. stable regimen of pd medications for 30 days prior to screening 6. ability to comply with the study procedures 7. if female, be either post menopausal for at least 2 years, surgically sterilized or have undergone hysterectomy or, if of child bearing potential they must be willing to avoid pregnancy by using an adequate method of contraception as defined in section 6.4.10 for four weeks prior to, during and four weeks after the last dose of trial medication. for the purposes of this trial, women of childbearing potential are defined as all female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive. 8. willing and able to provide informed consent. exclusion criteria: 1. presence of other co morbid conditions that can contribute to gait dysfunction (orthopedic, rheumatologic, cardiac, other) 2. presence of freezing of gait (fog) only in medications on state 3. presence of freezing of gait (fog) only in medications off state 4. presence of significant cognitive dysfunction as determined by montreal cognitive assessment (moca) \<20 5. presence of clinically significant depression as determined by geriatric depression scale (gds)- 15\>5 6. presence of clinically significant hallucinations 7. inability to sign informed consent 8. participation in the physical therapy aimed at management of pd for the duration of the study (pt for orthopedic issues will be allowed) 9. contraindications for use of amantadine ( prior history of allergic reaction, history of known renal insufficiency with cr \> 2) 10. if female, be pregnant or lactating

Keywords: freezing of gait gait dysfunction
blood pressure measurement methods and prediction of intracranial hemorrhage after thrombectomy in stroke

Conditions: Acute Stroke; Blood Pressure; Cerebral Hemorrhage

Summary: a monocentric, non-randomized, prospective study in which each patient is his/her own control. the study investigates 2 methods of blood pressure measurement, within the first 24 hours after reperfusion, i) continuous measurement of blood pressure with the clearsight device (edwards) and ii) intermittent blood pressure measurements with cuff.

patients will be followed for 72 hours: * inclusion after reperfusion: clinical evaluation with nihss (national institute of health stroke score) score, measurement of blood pressure. * within 24 hours after reperfusion: blood pressure measurements * at 24 hours: nihss score. * between 24 and 36 hours :cerebral scan (assessment of hemorrhagic transformations and cerebral infarction volumes). * 72 hours after reperfusion: brain scanner in case of hyperdensity on the initial scanner

Eligibility criteria:
inclusion criteria: * occlusion of internal carotid arteries or proximal middle cerebral arteries (segment m1). * reperfusion after a thrombectomy procedure (defined by a 2b-3 thrombolysis in cerebral infarction (tici) score). exclusion criteria: * per-procedure hemorrhagic complications (prior to reperfusion) * known pregnancy

Keywords: acute stroke blood pressure cerebral hemorrhage
platelet augmentation using c. papaya leaf extract in live donor liver transplantation

Conditions: Thrombocytopenia

Summary: this project is a pilot randomized controlled trial aimed at investigating the potential of carica papaya leaf extract, available in a marketed pill formulation, in increasing platelet counts in live donor liver transplant recipients. carica papaya leaf extract has shown positive results in increasing platelet counts in various medical conditions such as dengue, immune thrombocytopenic purpura and chemotherapy induced thrombocytopenia. thrombocytopenia i.e. low platelet counts are a common occurrence in patients with chronic liver disease undergoing live donor liver transplant. it has been observed in previous studies that live donor liver transplant recipients who have persistent thrombocytopenia have significantly worse outcomes as compared to patients who have higher platelet counts. positive results in this study lead to further studies in assessing the impact of platelet augmentation in live donor liver transplant recipients.


Eligibility criteria:
inclusion criteria: * all consenting adults who are planned to undergo live donor liver transplant with platelet counts less than or equal to 75000/μl preoperatively. exclusion criteria: * patients who do not consent * alf \& aclf * pediatric transplant recipients * allergic to papaya * preoperative platelet counts \>75,000/ μl * recent history of dvt
effect of herbal extracts on gingival inflammation

Conditions: Gingivitis

Summary: the purpose of this study is to determine the minimal number of patches needed to get an effective response. patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study. after the first 20 patients \[5 cycles\], the effect of the number of patches will be tested. if there is no distinct reduction of beta glucuronidase in the gcf or of gingival index at the tested sites, more patients will be enrolled. patients will be added one cycle at a time with results being tested and analyzed. the enrollemnts of patients will stop when a dose response will be noticed or 15 cycles have been reached.


Eligibility criteria:
inclusion criteria: 1. age 18 -75. 2. severe localized gingival inflammation \[gi index 2 or greater exclusion criteria: 1. pregnancy or a wish to become pregnant during the study. 2. history of periodontal treatment within the last month. 3. antibiotic treatment within the last month 4. use of any antimicrobial mouthrinse within the last month. 5. participation in another trial one month prior to the study. 6. inability to behave compliant to the trial protocol by not placing all the patches given, or attending scheduled appointments. 7. systemic disease. 8. patients using salicylate

Keywords: gingivitis, localized treatment
hysteroscopic tubal occlusion using iso-amyl 2-cyano acrylate (amcrylate) in patients with hydrosalpinx

Conditions: Hydrosalpinx; Infertility, Female

Summary: the purpose of this study is to assess the effectiveness of hysteroscopic tubal application of iso amyl-2-cyanoacrylate in occluding uterine tubes of infertile women with hydrosalpinx, which would make it an easy approach for occluding tubes with hydrosalpinx prior to ivf.

the study will be conducted according to the guidelines on human experimentation of the 1975 declaration of helsinki. for all patients after taking signed informed consent , transcervical hysteroscopic cannulation of the proximal one centimeter of fallopian tubes with hydrosalpinx, will be done using a 4 fr, 42cm long, polyethylene ureteric catheter, where 0.5 ml of iso amyl-2-cyanoacrylate (amcrylate®) will be injected. all the surgical procedures will be performed without anesthesia, only premedication with an nsaid (e.g. naproxenr) is given orally one hour before the procedure. each patient will be under close observation for the first 24 hours postprocedure for any signs of inflammation as abdominal pain, tenderness or fever and for the vital data. hysterosalpingography will be done for all patients 0ne and 3 months postinjection to confirm tubal occlusion prior to ivf.

Eligibility criteria:
inclusion criteria: infertile women due to tubal factor with hydrosalpinx (unilateral or bilateral) prepared for ivf. exclusion criteria: 1. acute pelvic inflammatory disease. 2. intra uterine pathology
pilot study of functional and morphometric brain abnormalities related to adolescent idiopathic scoliosis (mor-fo-sia)

Conditions: Adolescent Idiopathic Scoliosis

Summary: adolescent idiopathic scoliosis (ais) is a complex deformity with different curves. these different curves may be distinguished by different physiopathologic mechanisms. without fully convincing model of the emergence and development of ais, their multifactorial nature seems evident. several pathophysiological theories involving the central nervous system have been proposed: the ais would be associated with disturbances of proprioceptive or sensory perception, and/or with integration of this information. this would result in an abnormal body image, responsible for sensorimotor asymmetry that may promote or cause the deformation. the main aim of this study is to find cortical and subcortical morphometric differences in the most common population of ais (right thoracic ais) compared to healthy adolescent control girls. secondary objectives are to study the cerebral white matter of the same groups (fractional anisotropy in the main white matter tracts), and activation of sensorimotor neural networks (fmri activation and functional brain connectivity). abnormalities of the studied parameters may be used as biomarkers for ais diagnosis and classification.


Eligibility criteria:
inclusion criteria: * female * between 14 and 16 years old * normal neurological examination * right handed * informed consent * informed consent form signed by a parent or a holder of parental authority * affiliated to medical insurance * negative urine pregnancy test for patients (a-std) : right thoracic scoliosis with a cobb angle between 20 and 40° for healthy volunteers (a-n) : no clinical scoliosis exclusion criteria: * pregnant or lactating woman * antecedents of cranial trauma or cranial intervention, of migraine, of spinal trauma, of scoliosis intervention * no idiopathic scoliosis * contraindications to mri * patient with a legal protection measure

Keywords: scoliosis mri (magnetic resonance imaging)
ultrasound guided autologous blood injection in temporomandibular joint dislocation

Conditions: Temporomandibular Joint Dislocation

Summary: the aim of this study is to compare the accuracy and effectiveness of ultrasound (us) guided autologous blood injection (abi) versus non- guided technique for the treatment of chronic recurrent temporomandibular joint dislocation

all patients involved in this study will be divided randomly to two different groups and injected with autologous blood into joint space and pericapsular tissue. study group (group a) will be injected with autologous blood with ultrasound guidance. control group (group b) will be injected with autologous blood without us guidance. anatomical landmarks and tactical sense will be followed only. the operation will be done under local anesthesia ( auriculotemporal nerve block ) the skin overlying the temporomandibular joint will be scrubbed by an antiseptic solution and the area will be isolated with sterile towels. external auditory canal will be blocked with cotton. about 3 ml of blood will be withdrawn from patient's antecubital fossa, of which 2 ml injected intra-articular and 1 ml in the pericapsular tissue (pt) the procedure should be repeated on the opposite side in case of bilateral involvement.

Eligibility criteria:
inclusion criteria: * patient with at least 3 episodes of temporomandibular joint dislocation in the past 6 months. * necessitating a visit to the emergency room or trained professional to reduce the dislocation. * radiological evidence of displacement of condylar head beyond the articular eminence on wide mouth opening. * maximum mouth opening (mmo) more than 40 mm. * unilateral or bilateral. * over 18 years of age. * both gender males or females. exclusion criteria: * patient having inflammatory temporomandibular joint disease like tuberculous arthritis, rheumatoid arthritis. * patients with bleeding disorders, pregnancy or bony pathology of temporomandibular joint . * allergy to local anesthetic. * severe epilepsy or parkinson's disease. * patient on anti-depressants or anti-psychotics. * inability to follow-up the patient during the entire follow-up period. * patients who had recent fracture at temporomandibular joint level or who had previous surgical interference to temporomandibular joint . * refused to sign the written informed consent were also excluded. * dystonia

Keywords: ultrasound autologous blood temporomandibular joint dislocation
study of tremelimumab in patients with advanced solid tumors

Conditions: Urothelial Bladder Cancer; Triple-negative Breast Cancer; Pancreatic Ductal Adenocarcinoma

Summary: a phase ii, multi-center, open-label study of tremelimumab monotherapy in patients with advanced solid tumors

this is an open-label, multi-center study to determine the efficacy and safety of tremelimumab in the treatment of different cohorts of patients with selected advanced solid tumors. if eligible and at the discretion of the investigator, after confirmed disease progression on tremelimumab monotherapy or during follow-up, patients will have the option of being sequenced to medi4736 (medimmune 4736) monotherapy or medi4736 + tremelimumab combination therapy, for up to 12 months or until disease progression, whichever comes sooner.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically documented solid tumor malignancies, including but not limited to 1 of the following: ubc, metastatic pdac, tnbc; are intolerant, are ineligible for, or have refused treatment with standard first-line therapy; 2. at least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with computed tomography (ct) (preferred) or magnetic resonance imaging (mri) scans and that is suitable for accurate repeated measurements. exclusion criteria: 1. any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment; 2. history of leptomeningeal carcinomatosis; 3. active or prior documented autoimmune or inflammatory disorders; 4. brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 14 days prior to study treatment start; 5. qt interval corrected for heart rate using fridericia's formula (qtcf) ≥470 ms; 6. known allergy or hypersensitivity to ip or any ip excipient

Keywords: urothelial bladder cancer, triple-negative breast cancer, pancreatic ductal adenocarcinoma, advanced solid tumors, tremelimumab, medi4736, orr
effects of hemoperitoneum driven carbon monoxide on post-traumatic stability and platelet aggregation

Conditions: Hemoperitoneum

Summary: our objective is to determine whether or not the presence of hemoperitoneum in trauma patients is associated with increased carbon monoxide (co) formation, and to determine if elevated carbon monoxide levels are associated with cardiovascular depression, impaired platelet aggregation, and/or multiple organ failure.


Eligibility criteria:
inclusion criteria: 1. hospitalized males 18 years of age or older, 2. diagnosis of isolated blunt or blunt and penetrating trauma, 3. admitted or expecting to be admitted to the intensive care unit, 4. on mechanical ventilation, and 5. written informed consent obtained exclusion criteria: 1. female gender, (females will be excluded from this study as the menstrual cycle and other estrogen variations are known to be associated with cyclic changes in co production adding a potential confounder to the interpretations of our findings.) 2. diagnosis of isolated penetrating trauma, 3. acute hemothorax or pneumothorax, 4. treatment with antiaggregants (asa, clopidogrel, aggrenox or ticlopidine), 5. enrollment in another research study, 6. prisoners, 7. inability to perform co measurement within 96 hours after hospital admission.